S&P 500   4,571.95 (-1.79%)
DOW   34,487.81 (-1.84%)
QQQ   393.19 (-1.63%)
AAPL   163.65 (+2.13%)
MSFT   330.27 (-1.89%)
FB   326.49 (-3.41%)
GOOGL   2,853.86 (-1.95%)
AMZN   3,503.45 (-1.63%)
TSLA   1,135.00 (-0.18%)
NVDA   322.06 (-3.51%)
BABA   126.80 (-3.65%)
NIO   38.97 (-3.68%)
CGC   10.37 (-6.24%)
AMD   156.68 (-3.23%)
GE   94.83 (-3.63%)
MU   84.61 (-1.78%)
T   22.62 (-5.32%)
F   19.21 (-2.34%)
DIS   143.51 (-2.91%)
ACB   6.18 (-4.04%)
AMC   33.90 (-7.98%)
PFE   53.86 (+2.79%)
BA   194.98 (-1.77%)
S&P 500   4,571.95 (-1.79%)
DOW   34,487.81 (-1.84%)
QQQ   393.19 (-1.63%)
AAPL   163.65 (+2.13%)
MSFT   330.27 (-1.89%)
FB   326.49 (-3.41%)
GOOGL   2,853.86 (-1.95%)
AMZN   3,503.45 (-1.63%)
TSLA   1,135.00 (-0.18%)
NVDA   322.06 (-3.51%)
BABA   126.80 (-3.65%)
NIO   38.97 (-3.68%)
CGC   10.37 (-6.24%)
AMD   156.68 (-3.23%)
GE   94.83 (-3.63%)
MU   84.61 (-1.78%)
T   22.62 (-5.32%)
F   19.21 (-2.34%)
DIS   143.51 (-2.91%)
ACB   6.18 (-4.04%)
AMC   33.90 (-7.98%)
PFE   53.86 (+2.79%)
BA   194.98 (-1.77%)
S&P 500   4,571.95 (-1.79%)
DOW   34,487.81 (-1.84%)
QQQ   393.19 (-1.63%)
AAPL   163.65 (+2.13%)
MSFT   330.27 (-1.89%)
FB   326.49 (-3.41%)
GOOGL   2,853.86 (-1.95%)
AMZN   3,503.45 (-1.63%)
TSLA   1,135.00 (-0.18%)
NVDA   322.06 (-3.51%)
BABA   126.80 (-3.65%)
NIO   38.97 (-3.68%)
CGC   10.37 (-6.24%)
AMD   156.68 (-3.23%)
GE   94.83 (-3.63%)
MU   84.61 (-1.78%)
T   22.62 (-5.32%)
F   19.21 (-2.34%)
DIS   143.51 (-2.91%)
ACB   6.18 (-4.04%)
AMC   33.90 (-7.98%)
PFE   53.86 (+2.79%)
BA   194.98 (-1.77%)
S&P 500   4,571.95 (-1.79%)
DOW   34,487.81 (-1.84%)
QQQ   393.19 (-1.63%)
AAPL   163.65 (+2.13%)
MSFT   330.27 (-1.89%)
FB   326.49 (-3.41%)
GOOGL   2,853.86 (-1.95%)
AMZN   3,503.45 (-1.63%)
TSLA   1,135.00 (-0.18%)
NVDA   322.06 (-3.51%)
BABA   126.80 (-3.65%)
NIO   38.97 (-3.68%)
CGC   10.37 (-6.24%)
AMD   156.68 (-3.23%)
GE   94.83 (-3.63%)
MU   84.61 (-1.78%)
T   22.62 (-5.32%)
F   19.21 (-2.34%)
DIS   143.51 (-2.91%)
ACB   6.18 (-4.04%)
AMC   33.90 (-7.98%)
PFE   53.86 (+2.79%)
BA   194.98 (-1.77%)
NASDAQ:OCUP

Ocuphire Pharma News Headlines

$3.77
-0.40 (-9.59%)
(As of 11/30/2021 12:57 PM ET)
Add
Compare
Today's Range
$3.70
$4.16
50-Day Range
$3.40
$5.38
52-Week Range
$3.35
$13.81
Volume
38,161 shs
Average Volume
1.06 million shs
Market Capitalization
$65.22 million
P/E Ratio
N/A
Dividend Yield
N/A
Beta
0.15

Media Mentions By Week



Ocuphire Pharma Media Sentiment

Each headline receives a score ranging from 2 (good news) to -2 (bad news). Our company news sentiment scores track the average news sentiment of articles about each company over the most recent 7 days in order to identify companies that are receiving positive press.

OCUP
News Sentiment

0.55

0.27

Average
Medical
News Sentiment

Media Coverage

We track news headlines from hundreds of news outlets and tag them by company. This chart compares the number of articles about this company in the last seven days compared with the average number of articles about this company on a typical week.

OCUP Articles
This Week

6

1

OCUP Articles
Average Week

Get Ocuphire Pharma News Delivered to You Automatically

Sign up to receive the latest news and ratings for OCUP and its competitors with MarketBeat's FREE daily newsletter.

Ocuphire Pharma (NASDAQ:OCUP) News Headlines Today

SourceHeadline
marketwatch.com logoOcuphire Pharma Shares Rise 42% After Trial Enrollment, Analyst Rating
marketwatch.com - November 24 at 1:50 PM
MarketBeat logoOcuphire Pharma Sees Unusually High Options Volume (NASDAQ:OCUP)
americanbankingnews.com - November 24 at 12:39 PM
MarketBeat logoHC Wainwright Begins Coverage on Ocuphire Pharma (NASDAQ:OCUP)
americanbankingnews.com - November 24 at 8:37 AM
MarketBeat logoOcuphire Pharma, Inc. (NASDAQ:OCUP) Given Average Recommendation of "Buy" by Analysts
americanbankingnews.com - November 24 at 7:16 AM
finance.yahoo.com logoOcuphire Announces Enrollment of First Patients in Second Phase 3 Pivotal Trial (MIRA-3) for Nyxol® in Reversal of Mydriasis (RM)
finance.yahoo.com - November 23 at 9:41 AM
MarketBeat logoOcuphire Pharma, Inc. (NASDAQ:OCUP) Short Interest Update
americanbankingnews.com - November 19 at 12:18 PM
msn.com logoOcuphire Pharma, Inc. (OCUP) Loses 17.9% in 4 Weeks, Here's Why a Trend Reversal May be Around the Corner
msn.com - November 18 at 1:01 PM
MarketBeat logoOcuphire Pharma, Inc. (NASDAQ:OCUP) Forecasted to Earn FY2021 Earnings of ($3.82) Per Share
americanbankingnews.com - November 17 at 8:18 AM
finance.yahoo.com logoQuite a few insiders invested in Ocuphire Pharma, Inc. (NASDAQ:OCUP) last year which is positive news for shareholders
finance.yahoo.com - November 15 at 5:04 PM
MarketBeat logoOcuphire Pharma (NASDAQ:OCUP) Announces Quarterly Earnings Results, Beats Estimates By $0.11 EPS
americanbankingnews.com - November 13 at 1:58 PM
fool.com logoOcuphire Pharma, Inc.(OCUP)
fool.com - November 13 at 7:36 AM
finance.yahoo.com logoOcuphire Announces Financial Results for the Third Quarter 2021 and Provides Corporate Update
finance.yahoo.com - November 12 at 7:49 AM
finance.yahoo.com logoOcuphire Invited to Present Clinical Data on Nyxol® and APX3330 at the American Academy of Ophthalmology 2021 Annual Meeting and Eyecelerator/AAO Meeting
finance.yahoo.com - November 1 at 10:37 AM
finance.yahoo.com logoOcuphire Announces Publications Featuring the Ref-1 Protein, a Transcription Factor Regulator, as a Novel Therapeutic Target for the Treatment of Neovascular Retinal Diseases
finance.yahoo.com - October 7 at 7:53 AM
finance.yahoo.com logoOcuphire’s Clinical Phase 2b Oral Drug Candidate APX3330 for Retina to be Featured at the OIS [email protected] and ASRS 2021 Annual Meeting
finance.yahoo.com - October 1 at 12:22 PM
finance.yahoo.com logoOcuphire Pharma Presenting at Three Upcoming Healthcare Conferences This Fall
finance.yahoo.com - September 27 at 8:01 AM
finance.yahoo.com logoOcuphire Pharma Presenting at Three Upcoming Healthcare Conferences This Fall
finance.yahoo.com - September 27 at 8:01 AM
finance.yahoo.com logoOcular Hypertension Market to Witness Robust Expansion at a 3.82% CAGR During the Study Period [2018-2030], Evaluates DelveInsight
finance.yahoo.com - September 23 at 1:37 PM
finance.yahoo.com logoOcuphire Pharma Presenting at Four Conferences in September
finance.yahoo.com - September 2 at 7:06 AM
finance.yahoo.com logoHere's Why We're Not Too Worried About Ocuphire Pharma's (NASDAQ:OCUP) Cash Burn Situation
finance.yahoo.com - August 9 at 6:16 PM
barrons.com logoOcuphire Pharma Inc.
barrons.com - August 7 at 12:37 AM
finance.yahoo.com logoOcuphire Pharma Presenting at Two Conferences in August
finance.yahoo.com - August 6 at 8:32 AM
finance.yahoo.com logoOcuphire Announces Publication in the Journal of Cellular Signaling Featuring its Oral Ref-1 Inhibitor APX3330 in Phase 2 Trial for the Treatment of Retinal Disease
finance.yahoo.com - July 22 at 9:51 AM
finance.yahoo.com logoOcuphire Selected to Present at Multiple Ophthalmic Conferences in July
finance.yahoo.com - July 13 at 9:14 AM
marketwatch.com logoOcuphire Pharma Trial for Presbyopia Treatment Meets Endpoints
marketwatch.com - June 30 at 8:55 AM
finance.yahoo.com logoOcuphire’s VEGA-1 Phase 2 Trial in Presbyopia Meets Primary and Secondary Endpoints
finance.yahoo.com - June 30 at 8:55 AM
finance.yahoo.com logoOcuphire Pharma: Keep Your Eye on this Stock
finance.yahoo.com - June 20 at 11:48 AM
nasdaq.com logoOcuphire Pharma (NASDAQ:OCUP) Is In A Good Position To Deliver On Growth Plans
nasdaq.com - June 11 at 7:29 PM
finance.yahoo.com logoOcuphire Announces Addition to the Russell Microcap® Index
finance.yahoo.com - June 11 at 8:31 AM
finance.yahoo.com logoOcuphire Announces Closing of $15 Million Registered Direct Offering Priced At-the-Market
finance.yahoo.com - June 8 at 7:39 PM
finance.yahoo.com logoOcuphire Announces Appointment of Jay S. Pepose, M.D., Ph.D. to Its Board of Directors
finance.yahoo.com - June 8 at 9:38 AM
marketwatch.com logoOcuphire Pharma Shares Drop 7% After Direct Offering Prices
marketwatch.com - June 5 at 12:06 AM
marketwatch.com logoOcuphire Pharma in Direct Offering for 3.1M Shares, 1.5M Warrants
marketwatch.com - June 4 at 1:46 PM
finance.yahoo.com logoOcuphire Announces $15 Million Registered Direct Offering Priced At-the-Market Under Nasdaq Rules
finance.yahoo.com - June 4 at 1:46 PM
finance.yahoo.com logoOcuphire to Host Key Opinion Leader Event on Nyxol® as a Potential New Treatment Option for Reversing Pharmacologically Induced Mydriasis
finance.yahoo.com - May 20 at 9:18 AM
finanznachrichten.de logoGlaucoma Market: Future Forecast Indicates Impressive Growth Rate at a CAGR of 6.88% During the Study Period [2018-2030], Asserts DelveInsight
finanznachrichten.de - May 19 at 5:18 PM
finance.yahoo.com logoOcuphire Granted Two New U.S. Patents Covering Late-Stage Drug Candidate Nyxol®, Including for the Treatment of Presbyopia
finance.yahoo.com - May 18 at 10:15 AM
finance.yahoo.com logoOcuphire Completes Enrollment in VEGA-1 Phase 2 Clinical Trial Investigating Nyxol® in Combination with Low-Dose Pilocarpine for Treatment of Presbyopia
finance.yahoo.com - May 12 at 8:10 AM
finance.yahoo.com logoOcuphire Announces Financial Results for the First Quarter 2021 and Provides Corporate Update
finance.yahoo.com - May 7 at 8:10 AM
finance.yahoo.com logoOcuphire’s APX3330 for Retinal Diseases to be Presented at the 2021 Association for Research in Vision and Ophthalmology (ARVO) Virtual Annual Meeting
finance.yahoo.com - April 22 at 8:32 AM
finance.yahoo.com logoOcuphire Pharma Starts Mid-Stage APX3330 Study In Diabetic Retinopathy Patients
finance.yahoo.com - April 8 at 5:51 PM
finance.yahoo.com logoOcuphire Initiates ZETA-1 Phase 2 Clinical Trial Investigating APX3330 in Diabetic Retinopathy
finance.yahoo.com - April 8 at 12:51 PM
benzinga.com logoAlliance Global Partners Initiates Coverage On Ocuphire Pharma with Buy Rating, Announces Price Target of $25
benzinga.com - April 6 at 7:38 AM
finance.yahoo.com logoOcuphire Pharma, Inc. Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
finance.yahoo.com - April 1 at 7:38 PM
finance.yahoo.com logoPresbyopia Treatment Market Size is Projected to Grow at a CAGR of 4% during the Study Period [2018-2030], Anticipates DelveInsight
finance.yahoo.com - March 30 at 1:44 PM
markets.businessinsider.com logoOcuphire Pharma Inc Registered Shs Overweight
markets.businessinsider.com - March 17 at 12:38 PM
finance.yahoo.com logoOcuphire Pharma Stock Is Trading Higher After Nyxol Aces Late-Stage Study
finance.yahoo.com - March 16 at 4:32 PM
finance.yahoo.com logoOcuphire Announces MIRA-2 Phase 3 Registration Trial for the Reversal of Mydriasis Meets Primary Endpoint
finance.yahoo.com - March 15 at 8:05 AM
finance.yahoo.com logoOcuphire Announces Financial Results for the Full Year 2020 and Provides Corporate Update
finance.yahoo.com - March 10 at 7:38 PM
finance.yahoo.com logoOcuphire Announces Publication of MIRA-1 Phase 2b Results in Optometry and Visual Science Demonstrating Reduction of Pharmacologically Induced Mydriasis by Nyxol®
finance.yahoo.com - March 5 at 12:14 PM
Get Ocuphire Pharma News Delivered to You Automatically

Sign up to receive the latest news and ratings for OCUP and its competitors with MarketBeat's FREE daily newsletter.

This page was last updated on 11/30/2021 by MarketBeat.com Staff

Resources

Premium Research Tools

MarketBeat All Access subscribers can access stock screeners, the Idea Engine, data export tools, research reports, and other premium tools.

Discover All Access

Market Data and Calendars

Looking for new stock ideas? Want to see which stocks are moving? View our full suite of financial calendars and market data tables, all for free.

View Market Data

Investing Education and Resources

Receive a free world-class investing education from MarketBeat. Learn about financial terms, types of investments, trading strategies and more.

Financial Terms
Details Here
MarketBeat - Stock Market News and Research Tools logo

MarketBeat empowers individual investors to make better trading decisions by providing real-time financial data and objective market analysis. Whether you’re looking for analyst ratings, corporate buybacks, dividends, earnings, economic reports, financials, insider trades, IPOs, SEC filings or stock splits, MarketBeat has the objective information you need to analyze any stock. Learn more about MarketBeat.

MarketBeat is accredited by the Better Business Bureau

© American Consumer News, LLC dba MarketBeat® 2010-2021. All rights reserved.
326 E 8th St #105, Sioux Falls, SD 57103 | U.S. Based Support Team at [email protected] | (844) 978-6257
MarketBeat does not provide personalized financial advice and does not issue recommendations or offers to buy stock or sell any security.

Our Accessibility Statement | Terms of Service | Do Not Sell My Information

© 2021 Market data provided is at least 10-minutes delayed and hosted by Barchart Solutions. Information is provided 'as-is' and solely for informational purposes, not for trading purposes or advice, and is delayed. To see all exchange delays and terms of use please see disclaimer. Fundamental company data provided by Zacks Investment Research.